Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × EPOCH protocol × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡